A Safety and Tolerability Study of RJX Drug Product in Healthy Participants
A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants
Sponsor: ERT: Clinical Trial Technology Solutions
Listed as NCT03680105, this PHASE1 trial focuses on Critical Limb Ischemia and remains completed. Sponsored by ERT: Clinical Trial Technology Solutions, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1
-
Mar 2019 — May 2020 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1
-
Oct 2018 — Dec 2018 [monthly]
Recruiting PHASE1
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ERT: Clinical Trial Technology Solutions
- ICON plc
- Reven Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .